96 results
8-K
EX-1.1
KALV
KalVista Pharmaceuticals Inc
16 Feb 24
KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants
4:32pm
subsidiaries make and keep accurate books and records and maintain a system of internal accounting controls designed to provide reasonable assurance that: (i … the Representatives shall have received the opinion and negative assurance letter of Fenwick & West LLP, counsel for the Company, dated as of such date, in form
424B5
KALV
KalVista Pharmaceuticals Inc
16 Feb 24
Prospectus supplement for primary offering
4:29pm
the underwriters take any responsibility for, and provide no assurance as to the reliability of, any other information that others may give you. You … with respect to the preliminary financial data. Accordingly, Deloitte & Touche LLP does not express an opinion or any other form of assurance
424B5
KALV
KalVista Pharmaceuticals Inc
14 Feb 24
Prospectus supplement for primary offering
5:13pm
the underwriters take any responsibility for, and provide no assurance as to the reliability of, any other information that others may give you. You should … with respect to the preliminary financial data. Accordingly, Deloitte & Touche LLP does not express an opinion or any other form of assurance with respect